N/A
Completed N=95
Identifying Therapeutic Targets of Accelerated Sarcopenia
Source: ClinicalTrials.gov NCT03118050 ↗Enrolled (actual)
95
Serious AEs
0.0%
Results posted
Dec 2025
Primary outcomePrimary: Leg Lean Mass — 0.35; -0.55; -0.80; -0.44 kg — p=<0.01
Summary
The proposed research is designed to identify the mechanisms that can accelerate loss of muscle size, strength and physical function in type 2 diabetes and with hospitalization in older persons. About ⅓ of older Americans have type 2 diabetes, and about ⅓ of the hospitalizations in the USA involve persons older than 65 year of age. The proposed research is relevant to the part of NIH's mission that pertains to development of the fundamental knowledge that will improve health and reduce the burdens of disability, because this work will provide the fundamental evidence to identify new targets for the development of innovative treatments to slow down muscle loss and disability in our aging society.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Leg Lean Mass |
0.35; -0.55; -0.80; -0.44; -0.66; -0.59 | <0.01 sig |
| SECONDARY Knee Extension Strength |
3; -12; -24; -23; -30; -14 | <0.01 sig |
Eligibility Criteria
Inclusion Criteria
- Body mass index: 8%
- Impairment in Activities of Daily Living
- >2 falls/year
- weight loss >5% in the past 6 months
- Exercise training (≥2 sessions/week) or ≥10, 000 steps/day
- Significant cardiovascular, liver, renal, blood, or respiratory disease
- Active cancer or infection
- Recent (within 3 months) treatment with anabolic steroids, systemic corticosteroids or estrogen.
- Alcohol or drug abuse
Data sourced from ClinicalTrials.gov (NCT03118050). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.